APOE and early-onset autosomal dominant Alzheimer disease: A larger Phase II trial also concluded that rosiglitazone did not improve cognitive function of patients with mild Alzheimer’s disease, although exploratory subgroup analysis revealed that patients without APOE ε4 allele, a strong genetic risk factor of Alzheimer’s disease, might be more responsive with rosiglitazone [228].